Cisplatinum and BCNU chemotherapy in primary glioblastoma patients

Journal of Neuro-Oncology

Volumn 94, Issue 1, 2009, Pages 57-62

  Silvani, Antonio ^a   Gaviani, Paola ^a   Lamperti, Elena A ^a   Eoli, Marica ^a   Falcone, Chiara ^a   DiMeco, Francesco ^a   Milanesi, Ida M ^a   Erbetta, Alessandra ^a   Boiardi, Amerigo ^a   Fariselli, Laura ^a   Salmaggi, Andrea ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

BCNU; Chemotherapy; Cisplatinum; Glioblastoma; Temozolomide

Indexed keywords

CARMUSTINE; CISPLATIN; ERYTHROPOIETIN; TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGED; ANEMIA; ANTICONVULSANT THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLIOBLASTOMA; HEARING LOSS; HUMAN; LEUKOPENIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VESTIBULOCOCHLEAR NERVE DISEASE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARMUSTINE; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67650500993     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9800-0     Document Type: Article

References (24)

1. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in GBM. N Engl J Med 352(10):997-1003. doi: 10.1056/NEJMoa043331
2. Kaina B, Christmann M, Naumann S, Roos WP (2007) MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 6(8):1079-1099. doi: 10.1016/ j.dnarep.2007.03.008
3. Tanaka S, Kobayashi I, Utsuki S, Oka H, Yasui Y, Fujii K (2005) Down-regulation of O6-methylguanine-DNA methyltransferase gene expression in gliomas by platinum compounds. Oncol Rep 14(5):1275-1280
4. D'Atri S, Graziani G, Lacal PM, Nisticò V, Gilberti S, Faraoni I, Watson AJ, Bonmassar E, Margison GP (2000) Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. J Pharmacol Exp Ther 294(2):664-671
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996. doi: 10.1056/NEJMoa043330
6. Walker MD, Alexander E Jr, Hunt WE et al (1978) Evaluation of BCNU and/ or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333-343
7. Walker MD, Green SB, Byar DP et al (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329
8. Brandes AA, Tosoni A, Amista P et al (2004) How effective is BCNU in recurrent GBM in the modern era? A phase II trial. Neurology 63:1281-1284
9. Chang SM, Prados MD, Yung WK et al (2004) Phase II study of neoadjuvant 1,3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: A North American Brain Tumor Consortium trial. Cancer 100:1712-1716. doi: 10.1002/cncr.20157
10. Raizer JJ, Malkin MG, Kleber M et al (2004) Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. Neuro-oncol 6:247-252. doi: 10.1215/ S1152851704000122
11. Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, Huang W, Parker R (2006) In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res 12(15):4523-4532. doi: 10.1158/1078-0432.CCR-05-1830
12. Boiardi A, Eoli M, Salmaggi A, Pollo B, Milanesi I, Broggi G, Silvani A (2000) Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas. J Neurooncol 49(1):71-75. doi: 10.1023/A:1006489919811
13. Silvani A, Eoli M, Salmaggi A, Lamperti E, Maccagnano E, Broggi G, Boiardi A (2004) Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. J Neurooncol 66(1-2):203-208. doi: 10.1023/B:NEON.0000013479.64348.69
14. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343(19):1350-1354. doi: 10.1056/NEJM200011093431901
15. Buckner JC, Ballman KV, Michalak JC, Burton GV, Cascino TL, Schomberg PJ, Hawkins RB, Scheithauer BW, Sandler HM, Marks RS, O'Fallon JR (2006) North Central Cancer Treatment Group 93-72-52; Southwest Oncology Group 9503 Trials. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. J Clin Oncol 24(24):3871-3879. doi: 10.1200/JCO.2005.04.6979
16. Frenay M, Giroux B, Khoury S, Derlon JM, Namer M (1991) Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur J Cancer 27(7):852-856
17. Fetell MR, Grossman SA, Fisher JD et al (1997) Preirradiation paclitaxel in GBM multiforme: Efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol 15:3121-3128
18. Ciusani E, Balzarotti M, Calatozzolo C, de Grazia U, Boiardi A, Salmaggi A, Croci D (2007) Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines. Oncol Res 16(10):453-463. doi: 10.3727/096504007783338340
19. Sher DJ, Henson JW, Avutu B, Hochberg FH, Batchelor TT, Martuza RL, Barker FG II, Loeffler JS, Chakravarti A (2008) The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed GBM. J Neurooncol 88(1):43-50
20. Osoba D, Brada M, Yung WK, Prados M (2000) Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent GBM multiforme. J Clin Oncol 18(7):1481-1491
21. Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, Mason W, Mirimanoff RO, Baumert BG, Eisenhauer E, Forsyth P, Bottomley A, EORTC Radiotherapy Group; National Cancer Institute of Canada Clinical Trials Group (2005) Health-related quality of life in patients with GBM: A randomised controlled trial. Lancet Oncol 6(12):937-944. doi: 10.1016/S1470-2045(05)70432-0
22. Sghirlanzoni A, Silvani A, Scaioli V, Pareyson D, Marchesan R, Boiardi A (1992) Cisplatin neuropathy in brain tumor chemotherapy. Ital J Neurol Sci 13(4):311-315. doi: 10.1007/BF02223095
23. Meyers CA, Brown PD (2006) Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 24:1305-1309. doi: 10.1200/JCO.2005.04.6086
24. Lamers LM, Stupp R, van den Bent MJ, Al MJ, Gorlia T, Wasserfallen JB, Mittmann N, Jin Seung S, Crott R, Uyl-de Groot CA (2008) Cost-effectiveness of temozolomide for the treatment of newly diagnosed GBM multiforme: A report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cancer 112(6):1337-1344. doi: 10.1002/cncr.23297